Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618043 | 0.85 | TRPV1 (0.59) | TRPV1ALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL1312094 | 0.81 | TRPV1 (0.74) | TRPV1MAOBALDH1A1CYP1A2MAPT | |
| SCHEMBL27034898 | 0.78 | KDM4E (0.62) | TRPV1ALDH1A1CYP1A2MAPTADRA2A | |
| SCHEMBL17737762 | 0.77 | NPC1 (0.66) | TRPV1CYP1A2ADRA2AADRA2BADRA2C | |
| SCHEMBL14665804 | 0.76 | ADRA2A (0.50) | ALDH1A1MAPTADRA2AADRA2BADRA2C | |
| SCHEMBL30034364 | 0.76 | TRPV1 (0.46) | TRPV1MAOBALDH1A1CYP1A2MAPT | |
| SCHEMBL8154848 | 0.76 | TRPV1 (0.66) | TRPV1MAOBALDH1A1CYP1A2MAPT | |
| SCHEMBL3759677 | 0.75 | TRPV1 (0.47) | TRPV1ALDH1A1ADRA2AADRA2BADRA2C | |
| SCHEMBL20901375 | 0.74 | SLC1A3 (0.41) | ALDH1A1CYP1A2RAB9AMEN1KMT2A | |
| SCHEMBL24652555 | 0.74 | ALDH1A1 (0.55) | TRPV1ALDH1A1CYP1A2MAPTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029378-B2 | Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| US-9029378-B2 | Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-05-12 | — | — | US | disclosed |
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-8901111-B2 | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | US | disclosed |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | US | disclosed |
| EP-2736899-A1 | SUBSTITUTED BICYCLIC AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-20140066412-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-12 | — | — | US | disclosed |
| US-20110230490-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230490-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230490-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-22 | — | — | US | disclosed |
| WO-2010141809-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141809-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010068452-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010068452-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230490-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | TRPV1 2339/4885MAOB 340/4885ALDH1A1 2084/4885 |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | TRPV1 2030/4885MAOB 404/4885ALDH1A1 2221/4885 |
| US-20140066412-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | TRPV1 2030/4885MAOB 404/4885ALDH1A1 2221/4885 |
| US-20120088741-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, APEH | TRPV1 1177/4885MAOB 103/4885ALDH1A1 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.